Integrated design and performance optimization of three-electrode sliding discharge plasma power supply

The three-electrode sliding dielectric barrier discharge(TES-DBD) plasma actuator significantly enhances the ionization rate and momentum exchange between charged particles and neutral particles by incorporating a parallel DC electrode into the standard DBD design. This design improves the body force and induced jet velocity while allowing flexible control of the induced jet angle, overcoming the limitations of discharge extension and uncontrollable direction in traditional DBD plasma actuators. An integrated plasma power supply has been designed specifically for TES-DBD plasma actuators, streamlining the power supply management. The methodology involves designing the circuit topology for the TES-DBD power supply, followed by simulating and validating its operating principles using Multisim software. The operational performance of the power supply is evaluated through a comprehensive analysis of its electrical,thermal, and aerodynamic properties specific to TES-DBD plasma actuation.

Neoadjuvant camrelizumab(an anti-PD-1 antibody)plus chemotherapy or apatinib(a VEGFR-2 inhibitor)for initially unresectable stage II–III non-small-cell lung cancer:a multicentre,two-arm,phase 2 exploratory study

This multicentre,two-arm,phase 2 study aimed to explore the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy or apatinib in patients with initially unresectable stage II–III non-small-cell lung cancer(NSCLC).Eligible patients regardless of PD-L1 expression received neoadjuvant camrelizumab 200 mg and platinum-doublet chemotherapy every 3 weeks(arm A)or those with PD-L1-positive tumors received neoadjuvant camrelizumab and apatinib 250 mg once daily(arm B),for 2–4 cycles,followed by surgery.The primary endpoint was major pathological response(MPR)rate.Thirty patients in arm A and 21 in arm B were enrolled.Surgery rates were 50.0%(15/30)in arm A and 42.9%(9/21)in arm B,with all patients achieving R0 resections.Of these patients,the MPR and pathological complete response rates were both 20.0%(95%CI 4.3–48.1)in arm A and were 55.6%(95%CI 21.2–86.3)and 11.1%(95%CI 0.3–48.2)in arm B,respectively.The corresponding objective response rates were 33.3%(95%CI 11.8–61.6)and 55.6%(95%CI 21.2–86.3).With a median follow-up of 22.4 months(95%CI 19.0–26.0),the median event-free survival was not reached(NR;95%CI 13.6-NR)in arm A and 16.8 months(95%CI 8.6-NR)in arm B.Grade 3 or above treatment-related adverse events occurred in eight(26.7%)patients in arm A and three(14.3%)in arm B.Biomarker analysis showed baseline TYROBP expression was predictive of treatment response in arm B.Neoadjuvant camrelizumab plus chemotherapy or apatinib exhibits preliminary efficacy and manageable toxicity in patients with initially unresectable stage II–III NSCLC.

Spatiotemporal evolution laws of sector-shaped dielectric-barrier-discharge plasma actuator

Dielectric barrier discharge(DBD)plasma actuators are widely used in active flow control due to their simple design and rapid responsiveness.However,they need more effectiveness and discharge extension.To overcome these limitations,a sector-shaped dielectric barrier discharge(SS-DBD)plasma actuator with an adjustable jet angle was developed to enhance flow control effectiveness.The flow field dynamics induced by the SS-DBD plasma actuator were quantitatively analyzed using particle image velocimetry(PIV).Experimental investigations showed that precise adjustments to the actuation voltage can modulate the maximum velocity of the induced jet.Furthermore,a quasi-linear relationship between the sector-shaped angles of the SS-DBD and the deflected jet angles was established,indicating that changes in the sector-shaped angles directly influence the direction of the deflected jet.This correlation enables precise control over jet angles,significantly enhancing flow control by adjusting the SS-DBD-PA's sector-shaped angle.